Close
Close

Kite Pharma, Inc. - Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma

Partner

Not provided

Rare Disease

Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma

Sponsor

Kite Pharma, Inc.

Access Program Information

This is a multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory transplant ineligible aggressive NHL.

Contact

Contact: Ali Tantino (215-591-1100)

Locations
  • United States
  • Tampa, Florida, United States
  • United States
  • Boston, Massachusetts, United States
  • United States
  • Houston, Texas, United States

Free Newsletter